Results 51 to 60 of about 130,251 (209)

Generation and characterization of MEK and ERK inhibitors- resistant non-small-cells-lung-cancer (NSCLC) cells

BMC Cancer, 2018
Background The RAS/RAF/MEK/ERK pathway is one of the most downregulated pathway in cancer. Inhibitors of RAF and MEK have established clinical use while ERK inhibitors recently faced the clinic.
Alice Iezzi, Elisa Caiola, Arianna Scagliotti, Massimo Broggini   +3 more
doaj   +1 more source

Concurrent MEK2 Mutation and BRAF Amplification Confer Resistance to BRAF and MEK Inhibitors in Melanoma

Cell Reports, 2013
Although BRAF and MEK inhibitors have proven clinical benefits in melanoma, most patients develop resistance. We report a de novo MEK2-Q60P mutation and BRAF gain in a melanoma from a patient who progressed on the MEK inhibitor trametinib and did not ...
Jessie Villanueva, Jeffrey R. Infante, Clemens Krepler, Patricia Reyes-Uribe, Minu Samanta, Hsin-Yi Chen, Bin Li, Rolf K. Swoboda, Melissa Wilson, Adina Vultur, Mizuho Fukunaba-Kalabis, Bradley Wubbenhorst, Thomas Y. Chen, Qin Liu, Katrin Sproesser, Douglas J. DeMarini, Tona M. Gilmer, Anne-Marie Martin, Ronen Marmorstein, David C. Schultz, David W. Speicher, Giorgos C. Karakousis, Wei Xu, Ravi K. Amaravadi, Xiaowei Xu, Lynn M. Schuchter, Meenhard Herlyn, Katherine L. Nathanson   +27 more
doaj   +1 more source

A signaling visualization toolkit to support rational design of combination therapies and biomarker discovery: SiViT [PDF]

, 2016
Targeted cancer therapy aims to disrupt aberrant cellular signalling pathways. Biomarkers are surrogates of pathway state, but there is limited success in translating candidate biomarkers to clinical practice due to the intrinsic complexity of pathway ...
Boiko, Andrei, Bown, James L., Goltsov, Alexey, Harrison, David J., Mullen, Peter, Robertson, Paul, Shovman, Mark   +6 more
core   +3 more sources

Combination treatment strategy for pancreatic cancer involving the novel HDAC inhibitor MPT0E028 with a MEK inhibitor beyond K-Ras status

Clinical Epigenetics, 2019
Background Oncogenic K-Ras signaling highly relies on the canonical Ras/MEK/ERK pathway to contribute to pancreatic cancer progression. However, numerous efforts of MEK inhibitors have failed to provide an optimal antitumor effect for pancreatic cancer ...
Min-Wu Chao, Li-Hsun Chang, Huang-Ju Tu, Chao-Di Chang, Mei-Jung Lai, Yi-Ying Chen, Jing-Ping Liou, Che-Ming Teng, Shiow-Lin Pan   +8 more
doaj   +1 more source

Overcoming steroid resistance in T cell acute lymphoblastic leukemia [PDF]

, 2016
In a Perspective, Pieter Van Vlierberghe and Steven Goossens discuss Meijerink and colleagues' findings on steroid resistance in pediatric T cell acute lymphoblastic ...
Goossens, Steven, Van Vlierberghe, Pieter   +1 more
core   +3 more sources

The enhanced in vivo activity of the combination of a MEK and a PI3K inhibitor correlates with [18F]-FLT PET in human colorectal cancer xenograft tumour-bearing mice.

PLoS ONE, 2013
Combined targeting of the MAPK and PI3K signalling pathways in cancer may be necessary for optimal therapeutic activity. To support clinical studies of combination therapy, 3'-deoxy-3'-[(18)F]-fluorothymidine ([(18)F]-FLT) uptake measured by Positron ...
Emma J Haagensen, Huw D Thomas, Ian Wilson, Suzannah J Harnor, Sara L Payne, Tommy Rennison, Kate M Smith, Ross J Maxwell, David R Newell   +8 more
doaj   +1 more source

MEK inhibitors, novel anti-adhesive molecules, reduce sickle red blood cell adhesion in vitro and in vivo, and vasoocclusion in vivo. [PDF]

PLoS ONE, 2014
In sickle cell disease, sickle erythrocyte (SSRBC) interacts with endothelial cells, leukocytes, and platelets, and activates coagulation and inflammation, promoting vessel obstruction, which leads to serious life-threatening complications, including ...
Rahima Zennadi
doaj   +1 more source

An integrative pharmacogenomics analysis identifies therapeutic targets in KRAS-mutant lung cancerResearch in context

EBioMedicine, 2019
Background: KRAS mutations are the most frequent oncogenic aberration in lung adenocarcinoma. KRAS mutant isoforms differentially shape tumour biology and influence drug responses.
Haiyun Wang, Qi Lv, Yue Xu, Zhaoqing Cai, Jie Zheng, Xiaojie Cheng, Yao Dai, Pasi A. Jänne, Chiara Ambrogio, Jens Köhler   +9 more
doaj   +1 more source

Rapid and dramatic responses to dabrafenib and trametinib in BRAF V600E‐mutated lung adenocarcinoma

Respirology Case Reports, 2021
V‐raf murine sarcoma viral oncogene homologue B1 (BRAF) is a proto‐oncogene that regulates cell proliferation and survival. BRAF V600E‐mutated lung cancer has aggressive characteristics and is resistant to chemotherapies.
Takayo Ota, Aya Okabayashi, Masahiro Fukuoka   +2 more
doaj   +1 more source

Sensitization of renal carcinoma cells to TRAIL-induced apoptosis by rocaglamide and analogs [PDF]

, 2018
Rocaglamide has been reported to sensitize several cell types to TRAIL-induced apoptosis. In recent years, advances in synthetic techniques have led to generation of novel rocaglamide analogs.
Brown, Lauren E., Henrich, Curtis J., Nalli, Ancy D., Porco, John A., Sayers, Thomas J., Thomas, Cheryl L.   +5 more
core   +2 more sources